Downstaging to Liver Transplant: Success Involves Choosing the Right Patient.
Downstaging
Hepatocellular carcinoma
Hepatocellular carcinoma therapy
Liver cancer
Liver transplantation
Outcomes
Journal
Clinics in liver disease
ISSN: 1557-8224
Titre abrégé: Clin Liver Dis
Pays: United States
ID NLM: 9710002
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
entrez:
5
10
2020
pubmed:
6
10
2020
medline:
21
10
2021
Statut:
ppublish
Résumé
Hepatocellular carcinoma is a rising indication for liver transplantation in the United States. Downstaging, defined as the reduction of tumor burden using local-regional therapy into Milan criteria, opens an avenue to access cure through transplant for patients who traditionally would not qualify. Approaching the selection of downstaging candidates through an assessment of hepatic function, staying within a modest expansion of tumor burden, and incorporation of serologic/imaging markers for tumor biology provide the best chance for successful downstaging. Following well-defined downstaging protocols with built-in failure criteria ensures excellent post-transplant outcomes.
Identifiants
pubmed: 33012452
pii: S1089-3261(20)30056-8
doi: 10.1016/j.cld.2020.07.005
pii:
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
665-679Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure N. Mehta has served on advisory boards for WAKO Diagnostics and has received institutional research funding from Wako Diagnostics, Glycotest, and Target Pharmasolutions. K. Zhou reports institutional research funding from Gilead Sciences.